<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692949</url>
  </required_header>
  <id_info>
    <org_study_id>17123</org_study_id>
    <secondary_id>J1H-MC-LAJA</secondary_id>
    <nct_id>NCT03692949</nct_id>
  </id_info>
  <brief_title>A Study of LY3451838 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, and Pharmacokinetics Study of LY3451838 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has two parts. In Part A, single increasing doses of LY3451838 will be administered
      intravenously (into a vein). In Part B, a single dose of LY3451838 will be administered
      subcutaneously (just under the skin).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any Treatment Emergent Adverse Event</measure>
    <time_frame>Baseline through twenty weeks</time_frame>
    <description>Serious and other non-serious adverse events will be reported in the Adverse Events Module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events</measure>
    <time_frame>Baseline through twenty weeks</time_frame>
    <description>Serious and other non-serious adverse events will be reported in the Adverse Events Module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve (AUC) of LY3451838</measure>
    <time_frame>Pre-dose through twenty weeks</time_frame>
    <description>Pharmacokinetics (PK): AUC of LY3451838</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of LY3451838</measure>
    <time_frame>Pre-dose through twenty weeks</time_frame>
    <description>PK: Cmax of LY3451838</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3451838 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses, administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3451838 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching single doses administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching single doses administered subcutaneously (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3451838</intervention_name>
    <description>One dose administered (IV)</description>
    <arm_group_label>LY3451838 Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3451838</intervention_name>
    <description>One dose administered SC</description>
    <arm_group_label>LY3451838 Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male participants must adhere to contraception restrictions

          -  Female participants must be of non-childbearing potential due to:

               -  Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical
                  condition such as anorexia nervosa and not taking medications that induced the
                  amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormone,
                  anti-estrogens, selective estrogen receptor modulators, or chemotherapy)

               -  Surgical sterilization

          -  Have a body mass index of 18 to 35 kilograms per square meter (kg/m²)

          -  Have clinical laboratory test results within normal reference range or with acceptable
             deviations

          -  Have an estimated glomerular filtration rate greater than or equal to (≥) 60
             milliliters per minute per 1.73 meters squared (mL/minute/1.73 m²) of body surface
             area

          -  Have venous access sufficient to allow for blood sampling

        Exclusion Criteria:

          -  Are currently enrolled in or discontinued from a clinical trial within the last 30
             days, or have previously completed or withdrawn from this study

          -  Have a history or presence of medical illness including, but not limited to, any
             cardiovascular, hepatic, respiratory, hematological, renal, endocrine, psychiatric or
             neurological disease, or any clinically significant laboratory abnormality

          -  Have history of or presence of uncontrolled asthma, significant atopy, or significant
             rheumatological or autoimmune diseases

          -  Have had lymphoma, leukemia, or any malignancy within the past 5 years, or breast
             cancer within the past 10 years (with some exceptions)

          -  Have used, or intend to use some prescription or over the counter medications,
             including herbal medications within 14 days prior to dosing

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) or Fridericia's corrected
             QT (QTcF)

          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV
             antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or
             positive hepatitis B surface antigen

          -  Have donated blood of more than 450 milliliters (mL) within the last 3 months

          -  Are unwilling to stop alcohol consumption while resident in the Clinical Research Unit
             (CRU)

          -  Have an average weekly alcohol intake that exceeds 21 units per week for males and 14
             units per week for females (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL
             of wine; 1.5 oz or 45 mL of distilled spirits)

          -  Current smoker of more than 10 cigarettes or equivalent per day and unable to stop
             smoking while in the CRU

          -  Have an abnormal blood pressure

          -  Have clinically significant proteinuria or hematuria

          -  Positive findings for known drugs of abuse

          -  Have received treatment with biologic agents within 3 months or 5 half-lives
             (whichever is longer)

          -  Have clinically significant allergies, or intolerance to corticosteroids, or severe
             post treatment hypersensitivity reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 1, 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

